Cancer News: Leukemia and lymphoma
The US FDA has approved the first gene therapy for use against a type of blood cancer in the United States.
According to new research, some chronic myeloid leukemia (CML) patients may benefit from stopping their Tyrosine Kinase Inhibitor (TKI) treatments.
Chemotherapy following radiotherapy can improve progression-free survival (PFS) in patients with follicular lymphoma.
Advanced non-Hodgkin lymphoma ((NHL) patients receiving T-cell treatment, JCAR014 and chemotherapy had a complete response, new data show.
Key findings of the studies including ofatumumab, ponatinib, liposomal vincristine and reduced-intensity therapy for the treatment of ALL patients.
Promising results from treatment options for older patients with acute myelogenous leukemia (AML) and chronic lymphocytic leukemia (CLL).
Venetoclax induced promising outcomes to acute myelogenous leukemia patients whose disease had relapsed or was resistant to chemotherapy, a trial shows.
REVLIMID® (lenalidomide) received approval by the European Commission for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
Hodgkin lymphoma patients remained disease-free for over five years after being treated with the immunotherapy brentuximab vedotin, new data shows.
US regulator approved the marketing of a molecular diagnostic test measuring BCR-ABL levels in patients with chronic myeloid leukemia (CML).
Immunotherapy drug blinatumomab extended patients life with relapsed acute lymphoblastic leukemia when compared to chemotherapy.
EU regulators approved ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL).
US regulators granted accelerated approval to nivolumab for the treatment of patients with classical Hodgkin lymphoma.
US regulators approved AbbVie’s drug venetoclax to treat patients with previously treated chronic lymphocytic leukemia.
Positron emission tomography-computed found to be a new standard for staging patients with Hodgkin lymphoma as well as for assessment of treatment response.
US regulators have approved obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with follicular lymphoma.
Childhood Hodgkin's lymphoma survivors are at risk of breast cancer say researchers, adding that early screening reduces risk of breast cancer death.
Novartis’ investigational drug, midostaurin, received breakthrough therapy designation for US regulators for acute myeloid leukemia.
Pediatric acute lymphoblastic leukemia patients treated with chemotherapy alone remain at risk for attention and learning problems later, researchers report.
US regulators approved Arzerra, to be used as an extended treatment against recurrent or progressive chronic lymphocytic leukemia.
A new study identifies the gaps in post-treatment care for adolescent and young-adult Hodgkin lymphoma survivors.
Breast cancer survivors at risk of developing leukemia due to chemotherapy and/or radiation share certain characteristics, a new analysis shows.
The drug Midostaurin added to standard chemotherapy improved survival in patients with acute myeloid leukemia carrying mutations in the FLT-3 gene, scientists report.
Blinatumomab proved to be efficient and safe for the treatment of adult patients with acute lymphoblastic leukemia.
Chronic lymphocytic leukemia patients decreased more the risk of death when treated with the cancer drug Imbruvica instead of the chemotherapy chlorambucil.
Complete surgical excision proved to be the best treatment for breast implant-associated anaplastic large-cell lymphoma patients as it led to low recurrence rates.
EU regulators approved blinatumomab for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia.
Patients with mantle cell lymphoma benefited from the drug combination of rituximab plus lenalidomide, a new study shows.
A short course of oral vemurafenib was found to be highly effective in patients with relapsed/refractory hairy cell leukemia, two separate, phase 2 studies reveal.
The European health regulators conditionally approved Blincyto, a treatment for acute lymphoblastic leukemia (ALL), a rare blood cancer.